ORAMED PHARMACEUTICALS INC.(ORMP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,922 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in ORMP
Events flagged as statistical outliers against ORMP's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-10
ORMP quality score dropped 40 points (56→16) on a new filing
View source filing →
ORMP Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for ORAMED PHARMACEUTICALS INC. (ORMP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ORMP at 44.4/100 on a 32-signal composite quality model, placing it at rank #1,922 of 2,962 stocks — the bottom half of the AI-ranked universe. ORMP scores in the top quartile across profitability (100.0), balance sheet strength (99.8), institutional flow (86.6). Areas of concern include revenue scale (1.5) and free cash flow (3.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.5/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of ORMP by reported 13-F value include MERCER GLOBAL ADVISORS, Aquamarine Financial (Cayman) Ltd, Gem Investment Advisors, based on the most recent SEC filings. ORMP trades on the Nasdaq exchange and files with the SEC under CIK 1176309. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ORMP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ORAMED PHARMACEUTICALS INC. directly from SEC EDGAR. ORAMED PHARMACEUTICALS INC.'s 13F Pro composite quality score has ranged between 8 and 45 since 2021, currently 44.4 — an improving long-term trajectory across 11 quarterly and live scoring snapshots.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
Operating Income
Total Assets
+128.6% YoYTotal Debt
Op. Cash Flow
Free Cash Flow
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $2.7M |
| Net Income | — | — | — | — | — | $-23.0M |
| Operating Income | — | — | — | — | — | $-24.2M |
| Total Assets | $369.6M +128.6% | $161.7M -12.2% | $184.2M +17.9% | $156.3M -3.7% | $162.3M +26.8% | $128.0M |
| Total Debt | — | — | — | $99.5M +1262.0% | $7.3M -41.7% | $12.5M |
| Operating Cash Flow | — | — | — | — | — | $-21.2M |
| Free Cash Flow | — | — | — | — | — | $-21.6M |
Get alerted when ORMP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ORAMED PHARMACEUTICALS INC. including:
Top Institutional Holders of ORMP
MERCER GLOBAL ADVISORS INC /ADV
$18.3M3,810,540 shAquamarine Financial (Cayman) Ltd
$12.1M2,512,175 shGem Investment Advisors, LLC
$9.6M1,998,802 shBlackRock, Inc.
$7.7M1,608,111 shMurchinson Ltd.
$6.2M1,290,294 shBML Capital Management, LLC
$4.2M866,269 shBOOTHBAY FUND MANAGEMENT, LLC
$2.8M578,638 shGEODE CAPITAL MANAGEMENT, LLC
$2.4M500,690 shGOLDMAN SACHS GROUP INC
$1.2M253,293 shSTATE STREET CORP
$1.2M242,100 sh
| Fund | Value | Shares |
|---|---|---|
| MERCER GLOBAL ADVISORS INC /ADV | $18.3M | 3,810,540 |
| Aquamarine Financial (Cayman) Ltd | $12.1M | 2,512,175 |
| Gem Investment Advisors, LLC | $9.6M | 1,998,802 |
| BlackRock, Inc. | $7.7M | 1,608,111 |
| Murchinson Ltd. | $6.2M | 1,290,294 |
| BML Capital Management, LLC | $4.2M | 866,269 |
| BOOTHBAY FUND MANAGEMENT, LLC | $2.8M | 578,638 |
| GEODE CAPITAL MANAGEMENT, LLC | $2.4M | 500,690 |
| GOLDMAN SACHS GROUP INC | $1.2M | 253,293 |
| STATE STREET CORP | $1.2M | 242,100 |
More Healthcare Companies
View all Healthcare →Put ORMP on your watchlist
Track score changes the day ORAMED PHARMACEUTICALS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ORMP a good stock to buy?
13F Pro's AI-powered analysis of ORAMED PHARMACEUTICALS INC. (ORMP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ORMP are available on the ORMP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ORMP is classified as a small company.
Which hedge funds own ORMP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ORMP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ORAMED PHARMACEUTICALS INC.'s investment landscape.